• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Research Fellows
    • Our History
    • Corporate Social Responsibility
    • Environmental Sustainability
  • R&D
    • Clinical Pipeline
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / AT7519 – CDK inhibitor2 / 20113 / 2011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly

2011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly

25 November 2011/in 2011, AT7519 – CDK inhibitor

2011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2011-11-25 13:59:542016-11-25 14:05:412011 EORTC: Phase 1 Study of AT7519M Short Infusion Twice Weekly

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results Link to: Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results Astex Pharmaceuticals Reports 2011 Third Quarter Financial Results Link to: 2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models Link to: 2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant GIST Models 2011 EORTC: AT13387 Anti-Tumor Activity in imatinib-sensitive and -resistant...
Scroll to top Scroll to top Scroll to top